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900 The Journal of Thoracic and CardioObjective: We sought to grow in vitro functional smooth muscle cells, chondrocytes,
and respiratory epithelium on a biologic, directly vascularized matrix as a scaffold
for tracheal tissue engineering.
Methods: Ten- to 15-cm–long free jejunal segments with their own vascular pedicle
were harvested and acellularized from donor pigs (n  10) and used as a vascular
matrix. Autologous costal chondrocytes, smooth muscle cells, and respiratory epithe-
lium and endothelial progenitor cells were first cultured in vitro and then disseminated
on the previously acellularized vascular matrix. Histologic, immunohistologic, molec-
ular imaging, and Western blotting studies were then performed to assess cell viability.
Results: The endothelial progenitor cells re-endothelialized the matrix to such an
extent that endothelial cell viability was uniformly documented through 2-(18F)-
fluoro-2=-deoxyglucose positron emission tomography. This vascularized scaffold
was seeded with functional (according to Western blot analysis) smooth muscle
cells and successfully reseeded with viable ciliated respiratory epithelium. Chon-
drocyte growth and production of extracellular cartilaginous matrix was observed as
soon as 2 weeks after their culture.
Conclusions: The fundamental elements for a bioartificial trachea were successfully
engineered in vitro in a direct vascularized 10- to 15-cm–long bioartificial matrix.
Future experimental work will be directed to give them a 3-dimensional aspect and
a biomechanical profile of a functioning trachea.
Tissue engineering applies the principles of engineering and lifesciences toward the development of biologic substitutes that restore,maintain, or improve tissue function.1 Its advantages over othertissue replacement techniques are several, such as use of autologouscells, nonimmunogenicity, no side-effects related to foreign graftmaterials, and potential to grow when implanted into children.2
On the basis of our previous experimental work with tracheal allotransplanta-
tion,3 generation of bioartificial autologous tissue in vitro,4,5 and airway engineering
patching in human subjects,6 we investigated the feasibility of engineering a directly
vascularized bioartificial matrix displaying all cellular functioning elements of the
trachea, and the results are presented.
Materials and Methods
All reagents were purchased from Merck (Darmstadt, Germany) and Sigma-Aldrich
(München, Germany), and all experiments were done at room temperature unless indicated
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TSotherwise. Cell-culture media and supplements were from Promo-
cell (Heidelberg, Germany). The applied antibodies were obtained
from Dako (Hamburg, Germany).
Animal Experiments
German landrace pigs (n  10; age, 3 months; body weight, 18-25
kg) were obtained from a local dealer (Tierzuchtanstalt Mariensee,
Germany) and underwent scaffold harvesting under sterile condi-
tions. All animals received human care in compliance with the
“Guide for the Care and use of Laboratory Animals” published by
the National Institutes of Health (National Institutes of Health
publication No. 85-23, revised 1996) after approval from our
institutional animal protection board (experiment No. 02-504).
General anesthesia was induced by means of continuous thiopental
sodium (Trapanal). and fentanyl infusion. A median laparotomy
was used to isolate a 10- to 15-cm–long segment of jejunum,
including its artery and vein pedicle. After systemic administration
of heparin (300 IE/kg), the feeding artery was cannulated with a 6F
catheter and flushed with 100 mL of 0.9% NaCl. The draining vein
was cannulated with an 8F catheter, and venous backflow was
controlled macroscopically. The intestinal lumen was flushed with
500 mL of 0.9% NaCl at 4°C containing antibiotic solution (3250
IE of neomycin and 250 IE of bacitracin) immediately after ex-
plantation. The fourth lumbar vertebral bone was punctured, and
50 mL of bone marrow was gathered to isolate porcine bone
marrow–derived precursor cells. Costal cartilage served for chon-
Figure 1. Histologic and functional characterization o
showing highly cross-linked collagen fibers. (Original
decellularized jejunal matrix. B, Immunofluorescent
(Original magnification 400.) The CD31-positive en
depicted by the asterisk. The collagen fibers of the
acellular scaffold (negative control) showing nearly
scaffold image. D, Activity distribution in reseeded Bidrocyte isolation. At the end of the operation, the animals were
The Journal of Thoracikilled by an anesthesia overdose. Respiratory epithelium (RE) was
obtained by postmortem tracheal brushing. The specimens were
stored at 4°C until further processing.
Matrix Preparation and Acellularization
The scaffold was decellularized after mechanical removal of the
small bowel mucosa by a modification of the method of Meezan
and colleagues7 and kept in cell type–specific medium at 37°C
until reseeding. Modifications were as follows. For decellulariza-
tion, the small bowel segment was incubated in 1% sodium azide
solution (2 hours at 4°C) under shaking conditions. An incubation
in 1 mol/L sodium chloride solution containing 2000 U DNase
Type I (2 hours at 37°C) followed to remove the cellular proteins.
The tissue was incubated twice in sodium deoxycholate/0.1%
sodium azide solution (5 hours at 4°C) to dissolve lipid membrane
proteins.
Culture of Bone Marrow–Derived Progenitor Cells
Ten milliliters of porcine bone marrow aspirate was mixed with
M199 cell-culture medium in a 1:1 volume and centrifuged (1500
rpm, 5 minutes, room temperature). The supernatant was dis-
carded, and the resulting cell pellet was resuspended in 2 mL of
culture medium and transferred onto a Percoll gradient (Amersham
Biosciences, Freiburg, Germany) for centrifugation (2200 rpm, 15
minutes, room temperature). The superficial 14 mL was preserved,
reseeded biologic scaffold. A, Decellularized matrix
nification 40, HE stain.) Inset, Macroscopic view of
ing for CD31 in re-endothelialized scaffold matrix.
lial cells appear green (arrow). Vascular lumen is
ix appear red (X). C, Nuclear thin-layer scanning of
orm distribution of radioactivity. Inset, Macroscopic
scaffold.f the
mag
stain
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matr
unif
oVaMmixed with 35 mL of culture medium, and rotated for another 5
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resulting cell pellet was resuspended in M199 culture medium and
disseminated on gelatin-coated culture dishes. For endothelial dif-
ferentiation, cells were maintained in endothelial cell basal me-
dium 2 supplemented with hydrocortisone (100 g/500 mL of
culture medium solution), fetal calf serum (FCS; 50 mL/500 mL),
porcine vascular endothelial growth factor (0.25 g/500 mL),
human basic fibroblast growth factor (5 g/500 mL), human
epidermal growth factor (2.5 g/500 mL), insulin-like growth
factor (10 g/500 mL), ascorbic acid, penicillin (100 IE/mL),
streptomycin (100 g/mL), and essential amino acids (500 mg/500
mL). For smooth muscle cell (SMC) differentiation, 450 mL of
smooth muscle basal medium 2 supplemented with FCS (10%),
penicillin (100 IE/mL), streptomycin (100 g/mL), human epithe-
lial growth factor (0.25 g/500 mL), human basal fibroblast
growth factor (1 g/500 mL), insulin (2.5 mg/500 mL); and
transforming growth factor 1 (TGF-1) (5 ng/ml, Sigma) was
used.
Re-endothelialization
For vascular re-endothelialization, the arterial pedicle was filled
with 2 mL of endothelial cell basal medium 2 culture medium
containing 5  106 trypsinized cells. A nonpulsatile medium
perfusion rate of 0.8 mL/min was implemented with a roller pump
(IPC; Ismatec, Glattbrugg, Switzerland) and steadily increased for
72 hours to 1.5 mL/min. This increased rate was maintained
unchanged throughout the experiments.
Positron Emission Tomography
Re-endothelialized biologic vascularized matrices (BioVaMs; n  3)
were positioned within 20 cm from the center of a high-resolution,
dedicated, positron emission tomography (PET), full-ring scanner
(HR; Siemens, Erlangen, Germany, and CPS, Knoxville, Tenn) and
perfused with prewarmed culture medium at 30°C. Radiolabeled
2-(18F)-fluoro-2=-deoxyglucose (FDG; 40  7.2 MBq) was injected
into the arterial pedicle. Washing in and washing out of the medium
was allowed for 90 minutes each, and transmission and emission
scans were performed after each step over 10 minutes. Thereafter, the
cell-culture medium was replaced with glucose-free phosphate-
Figure 2. Region-of-interest activity histogram of thin-
graft; 2, median activity of the negative controls; 3, Bio
radius from the arterial pedicle.buffered saline (PBS) containing 1 IU/mL insulin and 40 8.5 MBq
902 The Journal of Thoracic and Cardiovascular Surgery ● Deceof FDG, and the PET procedure was repeated. Acellular BioVaMs
served as controls (n  3). After correction for physical decay,
attenuation, and scatter (as measured with a delayed coincidence
channel), the data sets were reconstructed by means of an iterative
algorithm by a 256 matrix with 2.0-mm Gaussian prereconstruction
filtering. After triple washing by PBS rinsing at 25°C (identical for the
negative and positive controls), the scaffolds were thin-layer scanned
(Instant Imager; Packhard, Menden, Conn). The resulting PET images
and thin-layer scans were evaluated by the regions of interest tech-
nique.
Muscle Tube Formation
The decellularized tubular scaffold matrix was mounted in a spe-
cially designed perfusion device (bioreactor), and 1.5  106 cells
dissolved in 2.5 mL of cell-culture medium was injected into the
intestinal lumen. The conduits were rotated for 20 hours at 0.5 rpm
and 37°C to facilitate cellular adhesion to the matrix. Then grafts
were perfused with SMC culture medium by using a pulsatile flow
pump (313U; Watson & Marlow, Rommerskirchen, Germany) at
15 mL/min for 3 weeks.
Chondrocyte Isolation and Culture
Costal chondrocytes were isolated from donor animals and cul-
tured in a 3-dimensional biologic culture system, as previously
described.8 In brief, costal cartilage was minced into 1- to 3-mm
pieces and enzymatically digested with 0.2% collagenase II. The
digested cartilage suspension was filtered with a sterile 250-nm
nylon filter, and the reaction was stopped with BGJ medium
(Sigma) containing 10% FCS. After centrifugation at 6000 rpm,
1  106 cells were mixed with 500 L of liquid collagen matrix
generated from decellularized porcine intestinal segments that
were incubated with 0.2% collagenase II solution for 12 hours at
37°C.
RE Cultures
Isolated RE was cultured in 15% FCS Dulbecco’s modified Eagle
medium solution. For scaffold seeding, 2  105 cells/cm2 were
scans of a reseeded BioVaM: 1, background without
at arterial pedicle; 4-6, BioVaM at 20-, 40-, and 70-mmlayer
VaMdistributed on the matrix.
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ation into SMCs. A, SMCs seeded under nonpulsatile conditions on the scaffold expressing desmin. (Original
magnification 400.) B, Staining for desmin in SMCs seeded under pulsatile conditions (Original magnification
400.) The asterisk indicates lumen of tubular scaffold. C, Western blot analysis for -actin expression (41-kd
band) in seeded SMCs: lane 1, molecular weight marker; lane 2, porcine aorta (positive control); lane 3, primary
SMC culture (positive control); lanes 4 and 5, SMCs seeded on BioVaM.Figure 4. Chondrocyte differentiation on the matrix. A, Chondrocytes (black arrow) are spaciously separated and
grow in cartilage-specific lacunas. (Original magnification 200, HE stain). B, Azan blue staining of bioartificial
cartilage synthesized on the matrix: red, chondrocytes; dark blue, newly synthesized collagen (white arrow).
(Original magnification 200.) C, Western blot analysis for collagen II synthesis in cultured 3-dimensional
chondrocytes: lane 1, molecular weight marker; lane 2, porcine collagen II (positive control); lane 3, porcine
endothelial cells (negative control); lane 4, costal chondrocytes seeded on the matrix; lane 5, native porcine costal
cartilage.
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For Azan blue staining, 6-m paraffin–embedded cross-sections were
incubated for 15 minutes at 56°C in an azocamin solution, containing
1 mg/mL azocamin and 1% pure acetic acid. The specimens were first
rinsed in sterile water and then differentiated in a 1% aniline-alcohol
solution, followed by washing in 1% acetic acid. Sections were
stained in 5% phosphortingstic acid and anilin-blue-orange G-acetic
acid solution for 3 hours each before final fixation in an increasing
ethanol column and incubation with xylol. For hematoxylin and eosin
(HE) staining, scaffold samples were embedded in Tissue-Tek
(Sakura Finetek, Zouterwoude, Netherlands) and stored at -20°C.
Six-micrometer-thick cross-sections were prepared, fixed for 8 min-
utes in acetone at -20°C, and stained with HE.
Immunohistology
Immunohistochemical staining for characterization of the reseeded
scaffold was performed by use of the avidin-biotin-peroxidase
technique. Endothelial cells were characterized by the presence of
CD31 (MCA 1746; Serotec, Düsseldorf, Germany); SMCs by the
presence of desmin (DE-R-11, Dako), actin (clone 1A4, Dako),
and myosin (M7786, Sigma); and RE cells by the presence of villin
antibody (SM1373P; DPC, Bad Nauheim, Germany). A biotyni-
lated goat anti-mouse antibody (HL; Vector, Burlingame, Calif)
served as a secondary antibody. Streptavidin-peroxidase conjugate
was applied, and final staining was performed with diaminoben-
zidine slides and counterstained with hematoxylin. For fluores-
cence microscopy, a fluoresecein isothiocyanate–conjugated sec-
ondary antibody was used.
Western Blotting
For characterization of chondrocytes, matrix production proteins
were isolated and separated according to the NuPAGE Bis-Tris
Gel instructions (Invitrogen; Life Technologies, Madison, Wis) on
days 1, 3, 7, 10, and 14 of the culture period. Quantitative signal
detection was performed according to the instructions of the ECL
Western blotting detection and analysis system of Amersham
Biosciences (Freiburg, Germany). Prestained sodium dodecylsul-
fate–polyacrylamide gel electrophoresis standard marker with a
broad range from 6000 to 196,000 kd was used (Bio-Rad, Munich,
Germany). Native porcine cartilage served as a positive control,
and porcine endothelial cells and liquid biologic matrix served as
Figure 5. Cultured RE. A, Light microscopy showing is
indicate fibrillating cilias. B, Immunohistologic staini
asterisk depicts tubular lumen. (Original magnificationnegative controls.
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Results are presented as the number of observations  SD.
Results
Biologic Vascularized Matrix
The acellularization procedure resulted in 10- to 15-cm–
long (11.9  1.8 cm) vascularized scaffolds composed of a
dense layer of highly cross-linked collagen and elastin fibers
(Figure 1, A). Three weeks after reseeding the preserved vas-
cular network within the matrix with endothelial progenitor
cells (EPCs), the cells expressed the endothelium-specific
marker CD31 uniformly (Figure 1, B). PET staining showed an
accumulation of the FDG activity in the EPC-reseeded Bio-
VaMs predominantly located within the proximity of the arte-
rial pedicle and nearly uniformly distributed in the acellular
negative controls (Figure 1, C and D). FDG uptake was 452
72 Bq/mL in reseeded BioVaMs. Insulin stimulation amplified
the FDG uptake in viable cells and resulted in a 2.7  0.3
increased uptake (1225  147 Bq/mL, P  .05). Maximum
activity of the reseeded BioVaMs was 42 13 Bq/mm2 in the
thin-layer scanning (Figure 2), 6 3MBq/mm2 in the negative
controls, and 0.7 0.4 MBq/mm2 in the background (without
scaffold; P  .001) The accumulated activity in the negative
control did not increase after insulin application. The locore-
gional FDG uptake histologically paralleled the distribution of
the endothelial cell marker CD31.
Muscle Tube Formation
The bone marrow–derived progenitor cells seeded on the
tubular biologic scaffold differentiated into SMCs under
laminar perfusion, showing the tissue-specific expression of
intracellular desmin, myosin, and actin (Figure 3, A). SMCs
were arranged longitudinally along the matrix fibers. Pul-
satile stress supported the development of multiple cell
layers in vitro. Tissue maturation was detectable after 10
days by the SMC-induced assemblance of the matrix fibers
(Figure 3, B). Histologic findings were confirmed by West-
d cells. (Original magnification 400.) White arrows
r villin as a marker for cellular differentiation. The
.)olate
ng foern blot analysis staining for -actin (Figure 3, C).
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Costal chondrocytes expanded in vitro. The 3-dimensional
liquid biologic culture system afforded the spacious sepa-
ration for the growing chondrocytes, which is essential for
their functional differentiation. HE staining documented the
formation of cartilage-specific lacunas (Figure 4, A). After 7
days in culture, the chondrocytes started to produce a new
extracellular matrix, thus forming cartilaginous tissue (Fig-
ure 4, B). The protein-biochemical characterization of this
bioartificial cartilage showed the synthesis of collagen II,
which represents the major collagen fraction in hyaline
cartilage (Figure 4, C). There was no evidence of collagen
III and collagen X production. The generated cartilaginous
tissue displayed no graft rigidity.
Functional RE
RE cells proliferated in vitro. The applied culture conditions
suppressed bacterial overgrowth. Cilial movement as a marker
for functionality was detectable for more than 4 weeks in
culture (Figure 5, A). Immunohistologic staining for villin
remained positive in the RE cytoskeleton throughout cultiva-
tion (Figure 5, B).
Discussion
Successful clinical tracheal transplantation is still in its
infancy, despite a magnitude of experimental work done
over the past century.9 One possible explanation relates to
the intrinsic technical difficulties of finding an ideal tracheal
substitute on the one hand and the very limited clinical
indications on the other.10 Tissue engineering is gaining
increasing acceptance in cardiothoracic surgery and repre-
sents the most promising technique that might be able to
create a functional tracheal substitute in the near future.9
Our working hypothesis was to transpose the clinical expe-
rience of replacing the cervical esophagus with the free
jejunal segment11 in the domain of tracheal tissue engineer-
ing.
We first isolated and decellularized a 10- to 15-cm-long
porcine jejunal segment and reseeded its vascular network
with autologous endothelial cells. This reseeding process is
of paramount importance to avoid graft thrombosis and
failure.3 Three weeks after the reseeding process, the grafts’
vascular network was uniformly re-endothelialized with vi-
able autologous endothelial cells, as suggested by histologic
and molecular imaging studies. Future work must clarify
whether this vascular network can withstand the systemic
arterial pressure in vivo, whether the endothelial cells will
shear off on reperfusion, or both. Moreover, it has to be
addressed whether the venous draining system has a high-
or low-resistance regimen to minimize the risks of venous
vascular infarction.3
Next we investigated the feasibility of growing trachea-
specific tissue components on the vascularized matrix. Bone
The Journal of Thoracimarrow progenitor cells seeded on the matrix differentiated
into SMCs and formed a muscular tube, showing the char-
acteristic histologic and biochemical features of muscular
tissue. It remains to be explored whether the few cell layers
meet the functional and biomechanical demands of the
posterior tracheal wall in vivo. It is hoped that muscular
tube formation can be optimized by the use of mechanobio-
reactors during tissue cultivation, inducing mechanical
stress on the maturing tissue.12
Rigid tracheal hyaline cartilage is a prerequisite for tra-
cheal function. In our experiments we have shown that
costal chondrocytes are suitable for tissue engineering tra-
cheal cartilage. They produce cartilage-specific extracellu-
lar matrix and show the morphology of hyaline cartilage.8,13
Recently, it has been shown that bone marrow precursor
cells can be differentiated into chondrocytes.14,15 The ap-
plication of these techniques would make thoracic biopsies
to obtain primary costal chondrocytes superfluous, both
experimentally and clinically. In this study the generated
cartilage shows the morphologic and protein-biochemical
features of hyaline cartilage but probably does not have the
essential biomechanical properties to stabilize the scaffold
matrix to such an extent to prevent airway collapse when
implanted in vivo. However, we have recently shown that a
tissue-engineered fibromuscular patch implanted into the
human airway system undergoes a significant tissue matu-
ration process within the first 6 weeks after implantation,
resulting in a significant increased matrix rigidity.6
The high sensitivity of the airway epithelium to ischemic
injury is well described because it is experimentally known
that an intact epithelial lining is essential for tracheal function
to prevent bacterial colonization, infection, and consecutive
graft degeneration and occlusion.3,9 Therefore, a functional
epithelium is the cornerstone for the long-term functionality of
a long-segment airway substitute. In our series we were able to
cultivate respiratory epithelial cells over a period of 4 weeks.
That the cells showed ciliar activity in vitro does not mean per
se that they will keep their function in vivo because physio-
logic factors like air stream might induce shear stress affecting
cellular adherence, interfere with mucous production, or both.
In conclusion, this study provides evidence that 10- to
15-cm-long vascular scaffolds harboring viable chondro-
cytes, SMCs, and RE might be generated by using tissue-
engineering techniques. However, and frankly speaking, the
bioartificial tissue-engineered trachea is far from clinical
application because fundamental issues regarding function-
ality and biomechanics of the bioartificial vascular network
and the viability of the in vitro-generated tissue components
in the in vivo environment have to be addressed.
We thank Ingrid Meeder, Maike Haupt, and Annette Just for
their laboratory assistance. Fred Hofmann established the methods
for the quantitative Western blot analysis that were used in this
study.
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Discussion
Dr Yolonda Colson (Boston, Mass). Could you help us better
understand exactly how the layers are orientated? Do you place
one layer of the collagen and then a layer over the top of it and then
another layer, or is it that they are all plated at the same time and
they distribute within layers themselves? Second, for the collagen
and cartilage, is it laid out as actual rings, or is there a complete
layer running the whole length of the trachea?
Dr Walles. Those are important questions. We seeded all cell
types isolated and currently do not have grafts consisting of muscle
cells and cartilage and endothelial cells. Thus far, we are able to
coculture endothelial cells and SMCs to generate a muscular tube
with a vascular network, but we have not succeeded in seeding
cartilage on the same graft at this time. Very recently, we devel-
oped a bioreactor system that allows us to seed cartilage on a
matrix, as we have shown here, but I am not able to show any data
thus far. The chondrocytes are seeded in a liquid matrix that we
developed and that was recently published in the Annals. The
906 The Journal of Thoracic and Cardiovascular Surgery ● Decechondrocytes seeded in that liquid matrix form their own cartilage,
produce collagen, and can be transferred onto a scaffold by using
the liquid matrix to generate a complex, 3-dimensional cartilagi-
nous structure.
Dr Walter Weder (Zurich, Switzerland). As to the vascular-
ized matrix, thus far you have only reperfused ex vivo through this
recirculating system. You have been doing research with this
vascularized matrix for several years. Have you ever used it in
vivo? How are the coagulation problems in these small vessels?
Thus far everybody has failed to produce a bioengineered con-
struct with small vessels that does not immediately lead to coag-
ulation of these small vessels. Do you have any information on
this?
Dr Walles. Thank you for the question, Dr Weder. Yes, we
have been working on this concept for several years already. We
first started off by seeding the matrix with primary endothelial
cells that we obtained, for example, from saphenous vein seg-
ments. Matrices that were seeded with these cells were implanted
for up to 3 hours into animals to check for the problem of
thrombosis. After explantation, we did not see thrombosis in these
grafts. However, in the clinical setting the differentiation and use
of autologous bone marrow–derived cells into SMCs, chondro-
cytes, and endothelial cells would make additional biopsy proce-
dures to obtain vascular endothelium superfluous. Therefore, bone
marrow–derived endothelial precursor cells are now our preferred
cell type for bioartificial graft re-endothelialization. Apart from
this, it has been shown that endothelial cells of different vascular
regions show different function by expression, for example, of
endothelial nitric oxide synthase. We hypothesized that the only
way to create a functional bioartificial capillary system would
require endothelial precursor cells that have the potential to dif-
ferentiate into the endothelial subtypes that you need in your graft.
Dr Dao M. Nguyen (Bethesda, Md). This is a very interesting
concept. I have 2 questions for you. First, how do you address the
issues of the structural rigidity of your graft? Second, how about
the geometric form of your graft? Is it going to be straight, like a
trachea?
Dr Walles. I will start with your second question first. From
clinical experience, where you take a jejunal segment for esoph-
ageal reconstruction, you do not have a geometric problem. It is a
tube then, and I think we can generate the same in vitro.
As to the second question, the matrix itself withstands pressures
of about 200 cm H2O. If seeded, we can increase this to 300 cm
H2O. The limiting factor for generating tracheal substitutes thus far
is the lack of sufficient graft rigidity, so that it does not collapse
when you implant it orthotopically, for example, into an animal.
This rigidity is provided by the cartilage that is synthesized by the
chondrocytes. Thus far, our cartilage does not have the biome-
chanical properties to prevent collapse of the matrix. We are
currently trying to improve the biomechanical properties of our
bioartificial cartilage. The presence of sufficient airway rigidity is
definitely something that one later has to document in an animal
model after extensive in vitro graft evaluation.
mber 2004
